Articles

Find an Article

Filter articles

Applied Filters

Showing 291 to 300 of 314 results

Post-grant patent challenges in Europe and the US: harmony at last?

EU, US01-04-2013Jane Wainwright and Daniel Young

Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.

Generic battles: pay-for-delay in Brazil

Brazil01-04-2013Gabriel Di Blasi

While no court has tested it, Brazilian legislation seems to prohibit pay-for-delay settlements in the pharmaceutical industry. Gabriel Di Blasi argues that it’s time for a test case.

Who's first? New rules on filing patents

US01-04-2013MaryAnne Armstrong

On March 16, 2013, the ‘first inventor to file’ provisions of the AIA came into effect. MaryAnne Armstrong looks at the implications.

Moving forward: biologics and biocomparables in Mexico

Mexico01-04-2013Daniel Sánchez and Victor Ramirez

Biocomparable medicines are currently among the hottest topics in regard to life sciences legislation in Mexico. Daniel Sánchez and Victor Ramirez investigate.

Waiting to inhale: MannKind's diabetes strategy

US28-03-2013

For a young innovation company, IP protection is all about ensuring comprehensive coverage. LSIPR spoke to David Diamond of MannKind Corporation about its threats and opportunities.

Myriad: Keeping a low profile

US01-12-2012

The latest rulings in the controversial legal battle over breast cancer gene patents seem to have found two out of three issues in defendant Myriad Genetics’ favour, but legal counsel Ben Jackson isn’t too excited by the implications.

A step forward: new dosage patents in Mexico?

01-05-2012Pablo Fuentes

The status of patentability for new dosage regimes in Mexico is unclear, but there have been some positive signs, says Pablo Fuentes.

A question of fairness: preliminary injunctions in Mexico

01-05-2012Hedwig Lindner and Manuel Morante

The system governing preliminary injunctions for pharmaceutical patent infringement should be revised to stave off potential frivolous cases, say Hedwig Lindner and Manuel Morante.

Crossed wires: protecting medicines in Mexico

01-05-2012Daniel Sánchez and Victor Ramirez

When introducing medicinal products to any market, the strength of the trademark is crucial. But the Mexican system requires getting trademark approval from two different authorities.

Out in front: the Boston cluster

01-01-2012

When it comes to life sciences, Boston is out on its own. LSIPR takes a look at innovation in the Olde Towne.

Showing 291 to 300 of 314 results

LSIPR